Medicenna Therapeutics Corp MDNA.TO :
* MEDICENNA SELECTS ITS LEAD IMMUNO-ONCOLOGY CLINICAL CANDIDATE, MDNA19, FROM ITS IL-2 SUPERKINE PLATFORM
* MEDICENNA THERAPEUTICS CORP - MDNA19 DEMONSTRATES ROBUST EFFICACY AND SAFETY WITH OR WITHOUT CHECKPOINT INHIBITORS IN PRECLINICAL MODELS
* MEDICENNA THERAPEUTICS CORP - CLINICAL STUDIES EXPECTED TO COMMENCE IN 2020